Imugene’s CF33-hNIS (VAXINIA) & MAST Study Featured at ASCO GI Cancers Symposium
SYDNEY, AUSTRALIA / ACCESSWIRE / January 18, 2024 / Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, is pleased to announce further details from its poster presentation at the ASCO Gastrointestinal Cancers Symposium (ASCO-GI) curren…
Read More